查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1469105

抗肥胖药物市场：2024-2034

Anti-obesity Drugs Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 310 Pages | 商品交期: 最快1-2个工作天内

价格

预计到 2034 年，全球抗肥胖药物市场规模将以 21.2% 的复合年增长率成长。

肥胖增加：

在过去的几十年里，由于遗传、环境、社会经济和文化因素的综合作用，所有年龄和人口群体的肥胖率都急剧增加。 世界肥胖联合会估计，到2020年，全球约有7.7亿成年人将受到肥胖的影响，到2030年，这一数字预计将上升到10亿以上。 饮食习惯、久坐生活方式、城市化和全球化的变化导致了广泛的不健康饮食模式、体力活动水平的降低、体重过度增加以及与肥胖相关的健康併发症。 此外，肥胖不仅是一种独立的健康状况，也是许多慢性疾病的主要危险因素，包括2 型糖尿病、心血管疾病、某些癌症和肌肉骨骼疾病，对人口健康的影响使情况变得更糟。 肥胖的后果超出了个人健康结果，也带来了社会和经济负担，包括医疗费用增加、生产力下降和生活品质下降。 解决肥胖的多方面原因需要采取政策干预措施，旨在促进健康的生活方式，改善营养食品的获取，并创造支持身体活动的环境，包括基于社区的举措、教育运动和医疗保健策略的综合性多部门方法。 透过解决肥胖的根本原因并实施有效的预防和治疗措施，利害关係人可以减少肥胖的流行及其对全球健康和福祉的深远影响。

医疗支出增加：

随着全球肥胖率持续上升，卫生系统越来越多地分配资源用于旨在遏制这一趋势的干预措施。 这种支出的增加涵盖了各个方面，包括开发新的、更有效的抗肥胖药物的研发、对医疗保健专业人员的肥胖管理策略的教育和培训，以及患者的外展和支持计划。 此外，与肥胖相关的健康併发症（例如糖尿病、心血管疾病和某些癌症）的经济负担进一步强调了投资预防和治疗措施以减少这些下游健康成本的必要性。 此外，随着卫生系统转向以价值为基础的护理模式，优先考虑预防性干预和慢性病管理，药物治疗在全面的肥胖治疗计划中的作用正在受到强调。 儘管抗肥胖药物的初始成本看起来很高，但改善健康和降低与肥胖相关併发症相关的医疗成本的潜在长期效益往往超过成本。 总体而言，抗肥胖药物市场医疗保健支出的增加反映了对紧迫的公共卫生问题的策略性投资，并减轻了这一趋势的更广泛的社会和经济影响，凸显了在健康预算中优先考虑肥胖管理的重要性。

本报告调查了全球抗肥胖药物市场，并提供了市场概况、影响市场成长和市场机会的因素分析、市场规模趋势和预测、各个细分市场和地区的详细分析以及竞争情况，我们总结了现状、主要公司简介等

目录

第 1 章报告概述

第 2 章执行摘要

第3章市场概述

  • 主要发现
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
  • 抗肥胖药物分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 波特五力分析
  • PEST分析

第4章抗肥胖药物市场分析：依药物类型

  • 主要调查结果
  • 市场吸引力指数
  • 市场规模趋势与预测
  • 处方
  • 非处方药
    • 市场规模趋势/预测：按地区划分
    • 市占率：依地区划分

第5章抗肥胖药物市场分析：按作用机转

  • 主要调查结果
  • 市场吸引力指数
  • 市场规模趋势与预测
  • GLP-1激动剂
  • GIPR拮抗剂
  • 胰淀素受体激动剂
  • 脂肪□抑制剂
  • SNRI
  • 其他
    • 市场规模趋势/预测：按地区划分
    • 市占率：依地区划分

第6章抗肥胖药物市场分析：依给药途径划分

  • 主要调查结果
  • 市场吸引力指数
  • 市场规模趋势与预测
  • 口头
  • 静脉注射
  • 皮下注射
    • 市场规模趋势/预测：按地区划分
    • 市占率：依地区划分

第7章抗肥胖药物市场分析：依通路划分

  • 主要调查结果
  • 市场吸引力指数
  • 市场规模趋势与预测
  • 医院药房
  • 零售药局
  • 网路药局
    • 市场规模趋势/预测：按地区划分
    • 市占率：依地区划分

第8章抗肥胖药物市场分析：依地区

  • 主要调查结果
  • 市场规模趋势与预测

第9章北美抗肥胖药物市场分析

第10章欧洲抗肥胖药物市场分析

第11章亚太地区抗肥胖药物市场分析

第12章拉丁美洲抗肥胖药物市场分析

第13章中东与非洲抗肥胖药物市场分析

第14章公司简介

  • 竞争状况
  • 战略展望
  • Arena Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Carmot Therapeutics, Inc.
  • CHEPLAPHARM Arzneimittel GmbH
  • CohBar, Inc.
  • Curaxx Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hanmi Pharm Co., Ltd.
  • Merck &Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • VIVUS LLC
  • Zydus Lifesciences

第 15 章一般性评论/建议

  • Visiongain 概述
  • 建议
Product Code: PHA1327

The global Anti-obesity Drugs market is estimated to grow at a CAGR of 21.2% by 2034

The Anti-obesity Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increased Prevalence of Obesity

Over the past few decades, obesity rates have risen dramatically across all age groups and demographics, fuelled by a combination of genetic, environmental, socioeconomic, and cultural factors. The World Obesity Federation estimated that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Changes in dietary habits, sedentary lifestyles, urbanization, and globalization have contributed to the widespread adoption of unhealthy eating patterns and reduced physical activity levels, leading to excess weight gain and obesity-related health complications. Moreover, obesity is not only a standalone health condition but also a major risk factor for numerous chronic diseases, including type 2 diabetes, cardiovascular diseases, certain cancers, and musculoskeletal disorders, further exacerbating its impact on population health. The consequences of obesity extend beyond individual health outcomes to encompass societal and economic burdens, including increased healthcare costs, lost productivity, and diminished quality of life. Addressing the multifaceted drivers of obesity requires a comprehensive and multi-sectoral approach that encompasses policy interventions, community-based initiatives, education campaigns, and healthcare strategies aimed at promoting healthy lifestyles, improving access to nutritious foods, and creating supportive environments for physical activity. By tackling the root causes of obesity and implementing effective prevention and treatment measures, stakeholders can mitigate the escalating obesity epidemic and mitigate its far-reaching consequences on global health and well-being.

Rising Healthcare Expenditure

As obesity rates continue to climb globally, healthcare systems are increasingly allocating resources towards interventions aimed at combating this epidemic. This heightened expenditure encompasses various aspects, including research and development efforts to innovate new and more effective anti-obesity drugs, healthcare provider education and training on obesity management strategies, as well as patient outreach and support programs. Additionally, the economic burden of obesity-related health complications, such as diabetes, cardiovascular diseases, and certain cancers, further underscores the necessity of investing in preventive and therapeutic measures to mitigate these downstream health costs. Furthermore, as healthcare systems transition towards value-based care models that prioritize preventive interventions and chronic disease management, there is a growing emphasis on the role of pharmacotherapy in comprehensive obesity treatment plans. While the upfront costs of anti-obesity drugs may seem significant, they are often outweighed by the potential long-term benefits of improved health outcomes and reduced healthcare expenditures associated with obesity-related comorbidities. Overall, the rising healthcare expenditure in the anti-obesity drugs market reflects a strategic investment in addressing a pressing public health issue and underscores the importance of prioritizing obesity management within healthcare budgets to mitigate the broader societal and economic impacts of this epidemic.

What Questions Should You Ask before Buying a Market Research Report?

How is the Anti-obesity Drugs Market evolving?

What is driving and restraining the Anti-obesity Drugs Market?

How will each Anti-obesity Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Anti-obesity Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Anti-obesity Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Anti-obesity Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Anti-obesity Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Anti-obesity Drugs Market?

Where is the Anti-obesity Drugs Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Anti-obesity Drugs Market today, and over the next 10 years:

Our 310-page report provides 134 tables and 191 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Anti-obesity Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-obesity drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Drug Type

Prescription

OTC

Mechanism of Action

Glucagon like Peptide GLP-1 Agonists

Gastric inhibitory Polypeptide Receptor (GIPR) Antagonist

Amylin Receptor Agonist

Lipase Inhibitors

Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)

Others

Route of Administration

Oral

Intravenous

Subcutaneous

Distribution channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Poland

Belgium

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-obesity Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Arena Pharmaceuticals Ltd.

Bayer AG

Boehringer Ingelheim International GmbH

Carmot Therapeutics, Inc.

CHEPLAPHARM Arzneimittel GmbH

CohBar, Inc.

Curaxx Pharmaceuticals LLC

Eisai Co., Ltd.

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharm Co., Ltd.

Merck & Co., Inc.

Novo Nordisk A/S

Pfizer Inc.

Rhythm Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

VIVUS LLC

Zydus Lifesciences

Overall world revenue for Anti-obesity Drugs Market, 2024 to 2034 in terms of value the market will surpass US$78,000 million in 2034, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-obesity Drugs Market, 2024 to 2034 report help you?

In summary, our 310-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Anti-obesity Drugs Market 2024 to 2034, with forecasts for drug type, Mechanism of action, route of administration, and distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Anti-obesity Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 17 of the major companies involved in the Anti-obesity Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Anti-obesity Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Anti-obesity Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Prevalence of Obesity
      • 3.2.1.2 Growing Awareness of Health Risks Associated with Obesity
      • 3.2.1.3 Technological Advancements
      • 3.2.1.4 Favourable Government Policies to Address Obesity Epidemic
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Adverse Drugs Reactions Associated with Anti-obesity Drugs
      • 3.2.2.2 Adherence to Weight Management Medications
      • 3.2.2.3 Lack of Access to Affordable Anti-obesity Drugs
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Increasing Number of Individuals Grappling with Obesity
      • 3.2.3.2 Automation in Drug Development Technologies
      • 3.2.3.3 Utilization of Digital Platforms to Enhance Patient Engagement
  • 3.3 Anti-obesity Drugs Analysis
    • 3.3.1 Top Anti-obesity Products, by Revenue
    • 3.3.2 Pipeline Analysis by Phase
    • 3.3.3 New Product Launches
  • 3.4 COVID-19 Impact Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Anti-obesity Drugs Market Analysis by Drug Type

  • 4.1 Key Findings
  • 4.2 Drug Type Segment: Market Attractiveness Index
  • 4.3 Anti-obesity Drugs Market Size Estimation and Forecast by Type
  • 4.4 Prescription
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 OTC
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Anti-obesity Drugs Market Analysis by Mechanism of Action

  • 5.1 Key Findings
  • 5.2 Drug Type Segment: Market Attractiveness Index
  • 5.3 Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 5.4 GLP-1 Agonists
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 GIPR Antagonists
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Amylin Receptor Agonist
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Lipase Inhibitors
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 SNRI's
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Others
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Anti-obesity Drugs Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 6.4 Oral
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Intravenous
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Subcutaneous
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Anti-obesity Drugs Market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 7.4 Hospital Pharmacies
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Retail Pharmacies
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Online Pharmacies
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Anti-obesity Drugs Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Anti-obesity Drugs Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Anti-obesity Drugs Market Attractiveness Index
  • 9.3 North America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 9.5 North America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 9.6 North America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 9.7 North America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 9.8 North America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 9.9 U.S. Anti-obesity Drugs Market Analysis
  • 9.10 Canada Anti-obesity Drugs Market Analysis

10 Europe Anti-obesity Drugs Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Anti-obesity Drugs Market Attractiveness Index
  • 10.3 Europe Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 10.5 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 10.6 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 10.7 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 10.8 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 10.9 Germany Anti-obesity Drugs Market Analysis
  • 10.10 France Anti-obesity Drugs Market Analysis
  • 10.11 UK Anti-obesity Drugs Market Analysis
  • 10.12 Italy Anti-obesity Drugs Market Analysis
  • 10.13 Spain Anti-obesity Drugs Market Analysis
  • 10.14 Russia Anti-obesity Drugs Market Analysis
  • 10.15 Poland Anti-obesity Drugs Market Analysis
  • 10.16 Belgium Anti-obesity Drugs Market Analysis
  • 10.17 Rest of Europe Anti-obesity Drugs Market Analysis

11 Asia Pacific Anti-obesity Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
  • 11.3 Asia Pacific Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 11.6 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 11.7 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.8 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.9 Japan Anti-obesity Drugs Market Analysis
  • 11.10 China Anti-obesity Drugs Market Analysis
  • 11.11 India Anti-obesity Drugs Market Analysis
  • 11.12 Australia Anti-obesity Drugs Market Analysis
  • 11.13 South Korea Anti-obesity Drugs Market Analysis
  • 11.14 Singapore Anti-obesity Drugs Market Analysis
  • 11.15 Taiwan Anti-obesity Drugs Market Analysis
  • 11.16 Rest of Asia Pacific Anti-obesity Drugs Market Analysis

12 Latin America Anti-obesity Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Anti-obesity Drugs Market Attractiveness Index
  • 12.3 Latin America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 12.5 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 12.6 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 12.7 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.8 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.9 Brazil Anti-obesity Drugs Market Analysis
  • 12.10 Mexico Anti-obesity Drugs Market Analysis
  • 12.11 Argentina Anti-obesity Drugs Market Analysis
  • 12.12 Colombia Anti-obesity Drugs Market Analysis
  • 12.13 Rest of Latin America Anti-obesity Drugs Market Analysis

13 MEA Anti-obesity Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Anti-obesity Drugs Market Attractiveness Index
  • 13.3 MEA Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 13.5 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 13.6 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 13.7 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.8 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.9 GCC Anti-obesity Drugs Market Analysis
  • 13.10 South Africa Anti-obesity Drugs Market Analysis
  • 13.11 Rest of MEA Anti-obesity Drugs Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2022
  • 14.2 Summary of all Strategic Outlook
  • 14.3 Arena Pharmaceuticals Ltd.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
      • 14.3.3.3 Regional Market Shares, 2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Bayer AG
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2023
      • 14.4.3.2 R&D, 2017-2023
      • 14.4.3.3 Regional Market Shares, 2023
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Boehringer Ingelheim International GmbH
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 R&D, 2017-2022
      • 14.5.3.3 Regional Market Shares, 2022
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Carmot Therapeutics, Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Product Benchmarking
    • 14.6.4 Strategic Outlook
  • 14.7 CHEPLAPHARM Arzneimittel GmbH
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 CohBar, Inc.
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
    • 14.8.4 Strategic Outlook
  • 14.9 Curaxx Pharmaceuticals LLC
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 Eisai Co., Ltd.
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2022
      • 14.10.3.2 R&D, 2017-2022
      • 14.10.3.3 Regional Market Shares, 2022
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Eli Lilly and Co
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2023
      • 14.11.3.2 R&D, 2017-2023
      • 14.11.3.3 Regional Market Shares, 2023
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 F. Hoffmann-La Roche Ltd
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 GlaxoSmithKline Plc
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2023
      • 14.13.3.2 R&D, 2017-2023
      • 14.13.3.3 Regional Market Shares, 2023
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Hanmi Pharm Co., Ltd.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2017-2022
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Merck & Co., Inc.
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2017-2023
      • 14.15.3.2 R&D, 2017-2023
      • 14.15.3.3 Regional Market Shares, 2023
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Novo Nordisk A/S
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2022
      • 14.16.3.2 R&D, 2017-2022
      • 14.16.3.3 Regional Market Shares, 2022
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 Pfizer Inc.
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2017-2023
      • 14.17.3.2 R&D, 2017-2023
      • 14.17.3.3 Regional Market Shares, 2022
    • 14.17.4 Product Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Rhythm Pharmaceuticals, Inc.
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2017-2022
      • 14.18.3.2 R&D, 2017-2022
      • 14.18.3.3 Regional Market Shares, 2022
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Takeda Pharmaceutical Company Limited
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2017-2023
      • 14.19.3.2 R&D, 2017-2023
      • 14.19.3.3 Regional Market Shares, 2023
    • 14.19.4 Product Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 VIVUS LLC
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Financial Analysis
      • 14.20.3.1 Net Revenue, 2017-2023
      • 14.20.3.2 R&D, 2017-2019
      • 14.20.3.3 Regional Market Shares, 2023
    • 14.20.4 Product Benchmarking
    • 14.20.5 Strategic Outlook
  • 14.21 Zydus Lifesciences
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2017-2023
      • 14.21.3.2 R&D, 2017-2023
      • 14.21.3.3 Regional Market Shares, 2023
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Anti-obesity Drugs Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 2 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 7 Prescription Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 8 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 9 Anti-obesity Drugs Market by Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 10 GLP-1 Agonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 11 GIPR Antagonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 12 Amylin Receptor Agonist Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 13 Lipase Inhibitors Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 14 SNRI's Agonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 15 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 16 Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 17 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 18 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 19 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 20 Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 21 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 22 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 23 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 24 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 25 North America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 26 North America Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 27 North America Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 28 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 29 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 30 U.S. Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 31 Canada Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 32 Europe Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 33 Europe Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 34 Europe Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 35 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 36 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 37 Germany Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 38 France Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 39 UK Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 40 Italy Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 41 Spain Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 42 Russia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 43 Poland Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 44 Belgium Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 45 Rest of Europe Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 46 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 47 Asia Pacific Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 48 Asia Pacific Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 49 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 50 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 51 Japan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 52 China Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 53 India Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 54 Australia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 55 South Korea Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 56 Singapore Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 57 Taiwan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 58 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 59 Latin America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 60 Latin America Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 61 Latin America Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 62 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 63 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 64 Brazil Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 65 Mexico Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 66 Argentina Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 67 Colombia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 68 Rest of Latin America Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 69 MEA Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 70 MEA Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 71 MEA Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 72 MEA Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 73 MEA Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 74 GCC Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 75 South Africa Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 76 Rest of MEA Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 77 Strategic Outlook
  • Table 78 Arena Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Arena Pharmaceuticals Ltd.: Product Benchmarking
  • Table 80 Arena Pharmaceuticals Ltd.: Strategic Outlook
  • Table 81 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Bayer AG: Product Benchmarking
  • Table 83 Bayer AG: Strategic Outlook
  • Table 84 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Boehringer Ingelheim International GmbH: Product Benchmarking
  • Table 86 Boehringer Ingelheim International GmbH: Strategic Outlook
  • Table 87 Carmot Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Carmot Therapeutics, Inc.: Product Benchmarking
  • Table 89 Carmot Therapeutics, Inc.: Strategic Outlook
  • Table 90 CHEPLAPHARM Arzneimittel GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 CHEPLAPHARM Arzneimittel GmbH.: Product Benchmarking
  • Table 92 CHEPLAPHARM Arzneimittel GmbH.: Strategic Outlook
  • Table 93 CohBar, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 CohBar, Inc.: Product Benchmarking
  • Table 95 CohBar, Inc.: Strategic Outlook
  • Table 96 Curaxx Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Curaxx Pharmaceuticals LLC: Product Benchmarking
  • Table 98 Curaxx Pharmaceuticals LLC: Strategic Outlook
  • Table 99 Eisai Co. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Eisai Co. Ltd: Product Benchmarking
  • Table 101 Eisai Co. Ltd: Strategic Outlook
  • Table 102 Eli Lilly and Co: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Eli Lilly and Co: Product Benchmarking
  • Table 104 Eli Lilly and Co: Strategic Outlook
  • Table 105 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 F. Hoffmann-La Roche Ltd.: Product Benchmarking
  • Table 107 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 108 GlaxoSmithKline Plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 GlaxoSmithKline Plc: Product Benchmarking
  • Table 110 GlaxoSmithKline Plc: Strategic Outlook
  • Table 111 Hanmi Pharm Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Hanmi Pharm Co., Ltd.: Product Benchmarking
  • Table 113 Hanmi Pharm Co., Ltd.: Strategic Outlook
  • Table 114 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Merck & Co., Inc.: Product Benchmarking
  • Table 116 Merck & Co., Inc.: Strategic Outlook
  • Table 117 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Novo Nordisk A/S: Product Benchmarking
  • Table 119 Novo Nordisk A/S: Strategic Outlook
  • Table 120 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 Pfizer Inc.: Product Benchmarking
  • Table 122 Pfizer Inc.: Strategic Outlook
  • Table 123 Rhythm Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Rhythm Pharmaceuticals, Inc.: Product Benchmarking
  • Table 125 Rhythm Pharmaceuticals, Inc.: Strategic Outlook
  • Table 126 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 128 Takeda Pharmaceutical Company Limited: Strategic Outlook
  • Table 129 VIVUS LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 VIVUS LLC: Product Benchmarking
  • Table 131 VIVUS LLC: Strategic Outlook
  • Table 132 Zydus Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 Zydus Lifesciences: Product Benchmarking
  • Table 134 Zydus Lifesciences: Strategic Outlook

List of Figures

  • Figure 1 Anti-obesity Drugs Market Segmentation
  • Figure 2 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 3 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
  • Figure 4 Anti-obesity Drugs Mechanism of Action: Market Attractiveness Index
  • Figure 5 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 6 Anti-obesity Drugs Market Attractiveness Index by Region
  • Figure 7 Anti-obesity Drugs Market: Market Dynamics
  • Figure 8 Top 10 Most Obese Countries in the World
  • Figure 9 Prevalence of Obesity in Different Regions
  • Figure 10 Top Anti-obesity Products by Revenue, 2022
  • Figure 11 Anti-obesity Product Pipeline Analysis by Phase
  • Figure 12 Anti-obesity Products, New Product Launches
  • Figure 13 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 14 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 15 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 16 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 17 Anti-obesity Drugs Market: Porter's Five Forces Analysis
  • Figure 18 Anti-obesity Drugs Market: PEST Analysis
  • Figure 19 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 20 Anti-obesity Drugs Market Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 21 Anti-obesity Drugs Market Share Forecast by Drug Type 2024, 2029, 2034 (%)
  • Figure 22 Prescription Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 23 Prescription Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 24 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 25 OTC Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 26 Anti-obesity Drugs Market by Mechanism of Action: Market Attractiveness Index
  • Figure 27 Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 28 Anti-obesity Drugs Market Share Forecast by Mechanism of Action; 2024, 2029, 2034 (%)
  • Figure 29 GLP-1 Agonists Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 30 GLP-1 Agonists Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 GIPR Antagonists Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 32 GIPR Antagonists Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Amylin Receptor Agonist Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 34 Amylin Receptor Agonist Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Lipase Inhibitors Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 36 Lipase Inhibitors Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 SNRI's Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 38 SNRI's Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 40 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 42 Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 43 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 44 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Oral Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 47 Intravenous Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Subcutaneous Stimulator Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 49 Subcutaneous Stimulator Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
  • Figure 51 Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 52 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 53 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 54 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 55 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 56 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 57 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 58 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 59 Anti-obesity Drugs Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
  • Figure 60 Anti-obesity Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 61 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 62 North America Anti-obesity Drugs Market Attractiveness Index
  • Figure 63 North America Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 64 North America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 65 North America Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 66 North America Anti-obesity Drugs Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
  • Figure 67 North America Anti-obesity Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
  • Figure 68 North America Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 69 North America Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 70 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 71 North America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 72 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 73 North America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 74 U.S. Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 75 Canada Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 76 Europe Anti-obesity Drugs Market Attractiveness Index
  • Figure 77 Europe Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 78 Europe Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 79 Europe Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 80 Europe Anti-obesity Drugs Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
  • Figure 81 Europe Anti-obesity Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
  • Figure 82 Europe Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 83 Europe Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 84 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 85 Europe Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 86 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 87 Europe Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 88 Germany Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 89 France Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 90 UK Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Italy Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 92 Spain Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 93 Russia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 94 Poland Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 95 Belgium Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 96 Rest of Europe Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 97 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
  • Figure 98 Asia Pacific Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 99 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 100 Asia Pacific Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 101 Asia Pacific Anti-obesity Drugs Market Forecast by Drugs Type, 2024-2034 (US$ Million, AGR %)
  • Figure 102 Asia Pacific Anti-obesity Drugs Market Share Forecast by Drugs Type, 2024 & 2034 (%)
  • Figure 103 Asia Pacific Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 104 Asia Pacific Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 105 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 106 Asia Pacific Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 107 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 108 Asia Pacific Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 109 Japan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 110 China Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 111 India Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 112 Australia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 113 South Korea Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 114 Singapore Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 115 Taiwan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 117 Latin America Anti-obesity Drugs Market Attractiveness Index
  • Figure 118 Latin America Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 119 Latin America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 120 Latin America Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 121 Latin America Anti-obesity Drugs Market Forecast by Drugs type, 2024-2034 (US$ Million, AGR %)
  • Figure 122 Latin America Anti-obesity Drugs Market Share Forecast by Drug type, 2024 & 2034 (%)
  • Figure 123 Latin America Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 124 Latin America Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 125 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 126 Latin America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 127 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 128 Latin America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 129 Brazil Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 130 Mexico Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Argentina Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Colombia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 133 Rest of Latin America Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 134 MEA Anti-obesity Drugs Market Attractiveness Index
  • Figure 135 MEA Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 136 MEA Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 137 MEA Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 138 MEA Anti-obesity Drugs Market Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 139 MEA Anti-obesity Drugs Market Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 140 MEA Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 141 MEA Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 142 MEA Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 143 MEA Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 144 MEA Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 145 MEA Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 146 GCC Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 South Africa Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 148 Rest of MEA Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 149 Anti-obesity Market Company Share, 2022
  • Figure 150 Arena Pharmaceuticals Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 151 Arena Pharmaceuticals Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 152 Arena Pharmaceuticals Ltd.: Regional Market Shares, 2022
  • Figure 153 Bayer AG: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 154 Bayer AG : R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 155 Bayer AG: Regional Market Shares, 2023
  • Figure 156 Boehringer Ingelheim International GmbH: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 157 Boehringer Ingelheim International GmbH: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 158 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
  • Figure 159 Eisai Co. Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 160 Eisai Co. Ltd: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 161 Eisai Co. Ltd: Regional Market Shares, 2022
  • Figure 162 Eli Lilly and Co: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 163 Eli Lilly and Co: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 164 Eli Lilly and Co: Regional Market Shares, 2023
  • Figure 165 F. Hoffmann-La Roche Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 166 F. Hoffmann-La Roche Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 167 GlaxoSmithKline Plc: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 168 GlaxoSmithKline Plc: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 169 GlaxoSmithKline Plc: Regional Market Shares, 2023
  • Figure 170 Hanmi Pharm Co., Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 171 Merck & Co., Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 172 Merck & Co., Inc.: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 173 Merck & Co., Inc.: Regional Market Shares, 2023
  • Figure 174 Novo Nordisk A/S: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 175 Novo Nordisk A/S: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 176 Novo Nordisk A/S: Regional Market Shares, 2022
  • Figure 177 Pfizer Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 178 Pfizer Inc.: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 179 Pfizer Inc. Regional Market Shares, 2022
  • Figure 180 Rhythm Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 181 Rhythm Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 182 Rhythm Pharmaceuticals, Inc. Regional Market Shares, 2022
  • Figure 183 Takeda Pharmaceutical Company Limited: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 184 Takeda Pharmaceutical Company Limited: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 185 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2023
  • Figure 186 VIVUS LLC: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 187 VIVUS LLC: R&D, 2017-2019 (US$ Million, AGR%)
  • Figure 188 VIVUS LLC: Regional Market Shares, 2023
  • Figure 189 Zydus Lifesciences: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 190 Zydus Lifesciences: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 191 Zydus Lifesciences: Regional Market Shares, 2023